---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-318429"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2025-12-15T23:59:59+00:00"
generated_at: "2026-05-16T13:12:09.333360+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Immunome Phase 3 RINGSIDE trial of varegacestat meets primary endpoint with 84% risk reduction

## Summary
- Progression-free survival HR=0.16 (95% CI 0.071-0.375, p<0.0001) vs placebo in desmoid tumors.
- Confirmed ORR 56% with varegacestat vs 9% with placebo (p<0.0001); median tumor volume change -83% vs +11%.
- All key secondary endpoints met; safety consistent with GSI class (most common AEs: diarrhea 82%, fatigue 44%, rash 43%).
- NDA submission to FDA planned for Q2 2026; additional data to be presented at upcoming medical conference.

## SEC filing metadata
- accession: 0001193125-25-318429
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2025-12-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000119312525318429/0001193125-25-318429-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000119312525318429/d793961d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-318429
- JSON: https://secwatch.observer/filing/0001193125-25-318429.json
- Plain text: https://secwatch.observer/filing/0001193125-25-318429.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.